SETTLEMENT OF THE REQUIP® CLASS ACTION NOTICE TO USERS OF REQUIP®

This Notice contains information which should interest you. Please read it carefully.

This notice is directed to all persons who were prescribed ReQuip® (generic name: Ropinirole Hydrochloride).

On October 22, 2013, the Ontario Superior Court of Justice (the "Court") certified Action #09-CV-391674-00 CP [Grosu v. GlaxoSmithKline Inc. as a class proceeding (the "Class Action")]. The Class Action alleges that ReQuip® causes impulse control disorders such as pathological gambling, hypersexuality, compulsive shopping and binge eating.

You are a Class Member if you were resident in Canada (other than Quebec) and you were prescribed ReQuip® in Canada and ingested ReQuip at any time on or before October 22, 2013. The Opt-Out deadline for this class action passed on January 31, 2014 (and accordingly no Class Members may now opt out of this Class Action).

A settlement of the Class Action has now been reached by the parties, **subject to approval by the Court**. The settlement will be considered for Court approval at a hearing on **May 3, 2016** (the "Approval Hearing"), in Toronto, Ontario.

If you are a Class Member and you claim to have suffered damages related to an impulse control disorder, including pathological gambling, hypersexuality, binge eating or compulsive shopping, you are eligible to apply for compensation under the settlement by submitting a Questionnaire to Class Counsel.

Some Class Members have already submitted Questionnaires to Class Counsel, as part of a court-approved settlement negotiation process. If you are such a Class Member, you need <u>not</u> do anything further. You will be contacted by Class Counsel to be informed how the proposed settlement will address your claim. If you are not sure whether you have previously submitted a Questionnaire, you may contact Class Counsel at the address below.

If you are a Class Member who has not previously submitted a Questionnaire to Class Counsel, you may still seek compensation under the settlement by submitting a completed Questionnaire to Class Counsel by February 12, 2016. This deadline is important. If you fail to submit a Questionnaire by this deadline you will be forever disentitled from making a claim for compensation.

You may obtain the Questionnaire at http://www.thomsonrogers.com/requip or by contacting Class Counsel at the address below. Note that the Questionnaire must be accompanied by a doctor's letter confirming an impulse control disorder and medical,

pharmacy and financial records supporting your use of Requip and your claimed gambling losses, if any.

New claims will be subject to the same analysis and treatment as those claims previously submitted as part of the court-approved negotiation process. There is no guarantee, however, that submitting a claim, whether as part of the court-approved negotiation process or otherwise, will result in compensation to you.

Anyone wishing to make submissions for or against the proposed settlement at the Approval Hearing must send a request in writing with a summary of your submissions to Class Counsel at the address below, by no later than **April 1, 2016.** Persons making submissions by the deadline will be provided with further information on how they may participate in the Approval Hearing.

Subject to court approval, Class Counsel will be seeking the approval of total fees of approximately \$402,900.00 inclusive of all disbursements and applicable taxes. Class Counsel was retained on a contingent basis. Class Counsel was responsible for funding all disbursements incurred in pursuing this litigation.

No further notice will be given following the Approval Hearing unless ordered by the Court.

Further details of the settlement are available by contacting Class Counsel or by visiting www.thomsonrogers.com.

Questions for counsel from Class Members should be directed by email, fax, or telephone to:

Darcy R. Merkur Thomson, Rogers, Barristers and Solicitors 390 Bay Street, Suite 3100 Toronto, Ontario, M5H 1W2 Toll free: 1-888-223-0448, Fax: 416-868-3134 dmerkur@thomsonrogers.com